Rockwell Medical, Inc. · NASDAQ:RMTI

Rockwell Medical — Investor Presentation (March 2024)

17 slides from Rockwell Medical's investor presentation, Mar 21, 2024

  1. Slide 1: Investor Presentation

    (© ROCKWELL MEDICAL Investor Presentation March 21, 2024 RMTI Nasdaq Listec

  2. Slide 2: Forward-Looking Statements and Non-GAAP Measures

    Forward-Looking Statements and Non-GAAP Measures Certain statements in this presentation may constitute “forward-looking statements” within the meaning of federal securities laws, including, but not limited to, Rockwell's expectations regarding revenue, profitability, financial position, 2024, 2025

  3. Slide 3: Rockwell Medical At A Glance

    Rockwell Medical At A Glance * Healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Business © Largest supplier of liquid bicarbonate hemodialysis concentrates in the U.S. Overview * Second largest supp

  4. Slide 4: Executive Management Team

    Executive Management Team Mark Strobeck, Ph.D. Jesse Neri President and CEO SVP, Finance Aquio Asserno= ARUVANT Megan Timmins EVP, Chief Legal Officer and Secretary aramark Jr -SSERTIO= & SR One Symphony Health Zylam» Zylam TOPAZ Tim T. Chole SVP, Sales and Marketing Baxter 1G Cochin SGAMBRO. Watson

  5. Slide 5: Corporate Strategy

    Corporate Strategy C) Be the Global Leader in Hemodialysis Concentrates QO) Provide Customers with the Highest Quality and Most Reliable Products and Services () Achieve $100M+ Annual Net Sales and Sustain Profitability QO) Focus on Innovative, Long-Term Growth Opportunities © 2024 Rociwell Medicale

  6. Slide 6: Only Two Major Manufacturers and Suppliers of Concentrates

    Only Two Major Manufacturers and Suppliers of Concentrates Approximately 475,000 patients in the U.S. require in-center hemodialysis annually). ¢ a Hemodialysis is a Necessity for End Stage Renal Disease Patients * Each patient receives approximately 3 treatments per week, totaling ~150 in-clinic pr

  7. Slide 7: U.S. In-Center and Acute Care Hemodialysis Concentrates TAM

    U.S. In-Center and Acute Care Hemodialysis Concentrates TAM ~4-6% CAGR driven primarily by increasing number of patients suffering from end-stage kidney disease 2024 2028 SOURCE: CAGR based on “Rockwell Medical: Concentrates Growth Strategy Report”, L.E.K. Consulting LLC (2022) © 2024 Rockwell Media

  8. Slide 8: Growth Opportunities and Potential Additional Revenue Streams

    Growth Opportunities and Potential Additional Revenue Streams Geographic Expansion Market Consolidation Increase market share throughout the U.S. oo Several small, regional hemodialysis and internationally. Rockwell continues to concentrates manufacturers. Opportunity secure commercial partnerships

  9. Slide 9: Financials and Milestones

    (© ROCKWELL MEDICAL Financials and Milestones

  10. Slide 10: Significantly Improving Rockwell's Financial Health

    Significantly Improving Rockwell’s Financial Health Generated Highest Revenue and Gross Profit to Date, Achieved Profitability on Adjusted EBITDA Basis in Q4’23 Three Months Ended Twelve Months Ended December 31 December 31 fan ng a $ 83.6 Net Sales 22.1 19.3 72.8 Gross Profit 29 2.3 $ 8.7 Adjusted

  11. Slide 11: 2023 was a Transformative Year for Rockwell Medical

    2023 was a Transformative Year for Rockwell Medical | sNetSales Gross Profit (Loss) Gross Margin (in $ millions) (in $ millions) $15 2021 2022 2023-2024 (E) 2022 2023 ©—-2024(E) 2023 = 2024 (E) © 2028 Rockwell Mesa, ne. (ROCKWELL MEDICAL

  12. Slide 12: Achieved Profitability on an Adjusted EBITDA Basis in Q4'23

    Achieved Profitability on an Adjusted EBITDA Basis in Q4’23 Projects Profitability on an Adjusted EBITDA Basis for Full-Year 2024 (in $ millions) $(28.4) 2021 2022 2023 2024 (E) © 2028 Rockwell Mesa, ne. (ROCKWELL MEDICAL

  13. Slide 13: Continued Growth Expected in 2025 and Beyond...

    Continued Growth Expected in 2025 and Beyond... == == 2025+ 2025 > ~20% beset 2026+ > +25% Growth

  14. Slide 14: 2024 Projected Milestones

    2024 Projected Milestones Achieve profitability for the full-year 2024 on an adjusted EBITDA basis. Continue to optimize our business through improved processes and expanded automated manufacturing capabilities. Enhance our distribution capabilities through the modernization of our infrastructure an

  15. Slide 15: Why Invest in Rockwell Medical?

    Why Invest in Rockwell Medical? O) Experienced Management Team O) Large and Growing Market Opportunity C) Revenue-Generating Business C) Profitable, Strong Financials O) Attractive Valuation © 2024 Rockwell Medical, inc. ©) ROCKWEL! MEDICAL

  16. Slide 16: www.rockwellmed.com IR@rockwellmed.com

    www.rockwellmed.com IR@rockwellmed.com

  17. Slide 17: Reconciliation to GAAP Financial Measures

    Reconciliation to GAAP Financial Measures Non-GAAP Financial Measures To supplement the Company's financial results presented on a U.S. generally accepted accounting principles ("GAAP") basis, the Company has included information about non-GAAP measures of EBITDA ‘and adjusted EBITDA as useful opera

Rockwell Medical — Investor Presentation (March 2024) on 6ix